Neuromyelitis optica

This early-stage trial is testing whether adding the drug sivelestat to standard steroid therapy is safe and may help people during an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that can cause vision loss and paralysis. Seven parti…

This early-phase trial tests whether a new CAR T cell therapy called CC-97540 is safe for people with a rare autoimmune disease called neuromyelitis optica (NMOSD). The study will enroll 5 adults who are stable on current treatments. Researchers will check for side effects and wh…

This trial tests a drug called ripertamab in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. Participants receive the drug by IV infusion four times over 73 weeks and are monitored for …

This early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…

This study compares five FDA-approved drugs—rituximab, ravulizumab, inebilizumab, satralizumab, and eculizumab—to see which best prevents relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition that can cause vision loss and paralysis. …

This study tests a drug called ravulizumab in about 19 Chinese adults with a rare autoimmune disease called NMOSD. The goal is to see if it can reduce the number of disease attacks (relapses) and slow disability. Participants must have had at least one attack in the past year and…

This early-phase trial tests whether injecting stem cells from a relative's bone marrow into the spine is safe for people with a severe relapse of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. Only 6 adult…

This early-phase trial tests a new treatment called KSVCBD, a type of CAR-T cell therapy, for people with a severe autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD) that has not responded to standard treatments. The study will include 18 adults who test pos…

This early-phase trial will test a new treatment called QT-019C in up to 15 adults with relapsed or refractory neurological autoimmune diseases, including multiple sclerosis, neuromyelitis optica, and myasthenia gravis. The treatment uses donor-derived CAR T-cells that target two…

This early-stage trial is testing a new treatment called C-CAR168, which uses a patient's own immune cells modified to attack harmful cells in the body. It is for 15 adults with multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person syndrome that have …

This early-stage study tests a new cell therapy called HY001N in 15 adults with relapsed or treatment-resistant autoimmune neurological diseases like neuromyelitis optica. The main goal is to check safety and side effects, while also looking for signs of improvement in disability…

This study tests whether monoclonal antibodies can safely and effectively treat acute attacks of neuromyelitis optica spectrum disorder (NMOSD), a rare disease that causes inflammation in the eyes and spinal cord. Researchers will enroll 40 adults experiencing a recent flare-up a…

This study tests a drug called inebilizumab combined with a fast steroid taper in 25 people newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. The goal is to see if this approach can reduce…

This trial investigates whether the drug crisugabalin can reduce neuropathic pain in people with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition affecting the nerves. Participants will receive either crisugabalin or a placebo, and their pain levels wil…

This observational study looks at whether combining genetic information with standard clinical data can better predict who will develop multiple sclerosis after a first episode of optic neuritis (inflammation of the optic nerve). Researchers will follow 180 people aged 16 and old…

This study will look at balance, core strength, leg strength, walking ability, and fatigue in 32 children aged 6-18 with demyelinating diseases (conditions affecting the protective coating of nerves). Each child will undergo a single session of non-invasive tests like balance exe…

This study looks at 50 people with neuromyelitis optica spectrum disorder (NMOSD) who seem stable on rituximab treatment. Researchers want to see if hidden damage to brain cells, measured by a protein called GFAP and special MRI scans, can predict future relapses or worsening dis…

This study will follow 1,550 adults with various neurological autoimmune diseases—like multiple sclerosis, myasthenia gravis, and autoimmune encephalitis—to see how these conditions progress and respond to treatments in everyday medical practice. Researchers will measure disabili…

This study will compare 100 people with either multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) to find better ways to tell them apart. Researchers will measure specific proteins in the blood and look at MRI scans. The goal is to improve diagnosis and man…

This study will measure sex hormone levels in 4000 people with NMOSD, a rare autoimmune disease affecting the nerves. Researchers want to see if hormone changes are linked to the disease. Participants will give blood samples for hormone testing. The study does not test any new dr…

This study will compare how often autonomic nervous system problems occur in people with neuromyelitis optica spectrum disorder (NMOSD) versus multiple sclerosis (MS). Researchers will use questionnaires and bedside heart tests to measure symptoms like dizziness, bladder issues, …